The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Speakers' Bureau - AstraZeneca Japan
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
 
Atsushi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Kirin; Lilly Japan; Novartis; Taiho Pharmaceutical; Thermo Fisher Scientific
 
Ryota Saito
No Relationships to Disclose
 
Ryo Ko
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim; Pfizer; Taiho Pharmaceutical
Research Funding - MSD K.K; Nippon Boehringer Ingelheim
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Takeda
 
Ryo Morita
No Relationships to Disclose
 
Makoto Maemondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; GlaxoSmithKline; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Speakers' Bureau - AstraZeneca
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma; Taiho Pharmaceutical (Inst)
 
Satoshi Oizumi
Honoraria - AstraZeneca; Bristol-Myers Squibb K.K.; Chugai Pharma; Lilly; Merck; MSD K.K.; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb K.K.; Chugai Pharma; Daiichi Sankyo; Kissei Pharmaceutical; Merck; MSD K.K; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
 
Kazuhisa Takahashi
Speakers' Bureau - AstraZeneca
 
Hiroshi Kagamu
Honoraria - AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - ImmuniT Research Inc.
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Isobe
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim
 
Masahiro Seike
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Taiho Pharmaceutical
 
Toshiaki Kikuchi
Honoraria - Astellas Pharma; AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Janssen; Japan BCG Laboratory; Kyorin; Lilly; MSD; Mylan; Novartis; Ono Pharmaceutical; Pfizer; Roche; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Teijin Pharma
Consulting or Advisory Role - An2 Therapeutics; Janssen
Research Funding - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Kyowa Kirin Co., Ltd.; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Eisai (Inst)
 
Hajime Asahina
Honoraria - AstraZeneca Japan; Chugai Pharma; Kyowa Kirin; Lilly; MSD K.K; Ono Pharmaceutical
 
Kentaro Tanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb/Ono Pharmaceutical; Chugai/Roche; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma; Daiichi Sankyo/UCB Japan
 
Kenji Sugio
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - Covidien; Lilly Japan
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca; Takeda